# A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

Source: https://onco.cc/trials/nct07497386/  
OnCo record `nct07497386` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Trastuzumab, Trastuzumab rezetecan and Trastuzumab deruxtecan in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.

## Summary

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer is a phase 2 interventional study registered as NCT07497386 by Jiangsu HengRui Medicine Co., Ltd., with 150 participants planned, started 2026-04-28 and due to reach its primary completion in 2028-06. Interventions recorded: Trastuzumab Rezetecan for Injection and Trastuzumab Deruxtecan for Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07497386
- Phase: 2
- Setting: A Randomized, Open-Label, Multicenter Phase II Clinical Study of Different Doses of Trastuzumab Rezetecan for Injection or Trastuzumab Deruxtecan for Injection in the Treatment of Unresectable Locally Recurrent/Metastatic Breast Cancer With HR-Positive and HER2-Low Expression
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT07497386: https://clinicaltrials.gov/study/NCT07497386

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Trastuzumab](https://onco.cc/drugs/trastuzumab/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/), [Trastuzumab rezetecan](https://onco.cc/drugs/trastuzumab-rezetecan/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct07497386.json